Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
Launched by SANOFI · Nov 16, 2016
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
The total study duration per patient is approximately 28 weeks.
Gender
ALL
Eligibility criteria
- Inclusion criteria :
- • Type 2 diabetic adult patients treated with basal insulin, with or without oral anti-diabetic agents, with or without glucagon-like peptide-1 (GLP-1) receptor agonist
- • HbA1c \> 7.5%
- Exclusion criteria:
- • Patients with high dose of insulin (\>1.2 U/kg)
- • Use of prandial insulin
- • Change of dose of antidiabetic drugs within the last 8 weeks
- • Use of systemic glucocorticoids during at least 2 weeks in the last 12 weeks
- • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
About Sanofi
Sanofi is a global healthcare leader dedicated to empowering life through innovation in pharmaceuticals and vaccines. With a strong commitment to research and development, Sanofi focuses on addressing complex health challenges across various therapeutic areas, including diabetes, oncology, immunology, and rare diseases. The company leverages advanced science and technology to develop transformative therapies that improve patient outcomes. Through collaborative partnerships and a patient-centric approach, Sanofi strives to enhance global health and deliver sustainable solutions that meet the evolving needs of healthcare systems and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, , France
Alencon Cedex, , France
Ales, , France
Amiens Cedex 1, , France
Amilly, , France
Bagnols Sur Cèze, , France
Bar Le Duc, , France
Besancon, , France
Bethune Cedex, , France
Bondy, , France
Brest Cedex, , France
Brest, , France
Cahors Cedex 9, , France
Cannes, , France
Chalons En Champagne Cedex, , France
Chambery, , France
Cholet, , France
Clermont Ferrand, , France
Cognac, , France
Colmar, , France
Contamines Sur Arve, , France
Coudray, , France
Dijon, , France
Eaubonne, , France
Etampes, , France
Grenoble, , France
La Roche Sur Yon, , France
La Rochelle Cedex 1, , France
La Seyne Sur Mer, , France
Lamagistere, , France
Le Chesnay Cedex, , France
Le Creusot, , France
Le Mans Cedex 9, , France
Lens, , France
Lourdes, , France
Mantes La Jolie, , France
Marseille, , France
Marseille, , France
Maubeuge, , France
Merignac, , France
Montpellier, , France
Montpellier, , France
Montpellier, , France
Mulhouse, , France
Nancy, , France
Narbonne Cedex, , France
Nevers, , France
Nimes, , France
Noisy Le Grand, , France
Orleans, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Perigueux Cedex, , France
Pessac Cedex, , France
Pointe à Pitre, , France
Pontoise, , France
Pringy Cedex, , France
Reims Cedex, , France
Roubaix, , France
Roubaix, , France
Saint Brieuc, , France
Saint Pierre, , France
Saint Denis, , France
Saint Mandé, , France
Seclin, , France
Sete, , France
Strasbourg Cedex 2, , France
Strasbourg, , France
Suresnes, , France
Tarbes, , France
Toulouse Cedex 3, , France
Toulouse, , France
Toulouse, , France
Toulouse, , France
Tours, , France
Tours, , France
Valenciennes, , France
Vandoeuvre Les Nancy Cedex, , France
Venissieux, , France
Vichy Cedex, , France
Vichy, , France
Villeneuve Sur Lot, , France
Warloy Baillon, , France
Patients applied
Trial Officials
Clinical Sciences & Operations
Study Director
Sanofi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials